Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dare Bioscience Inc (DARE)

Dare Bioscience Inc (DARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,711
  • Shares Outstanding, K 8,700
  • Annual Sales, $ 2,810 K
  • Annual Income, $ -30,160 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 1.27
  • Price/Sales 9.91
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.66
  • Number of Estimates 2
  • High Estimate -0.52
  • Low Estimate -0.80
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +8.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.67 +22.08%
on 12/20/24
3.75 -13.07%
on 12/11/24
-0.04 (-1.21%)
since 11/27/24
3-Month
2.67 +22.08%
on 12/20/24
4.60 -29.13%
on 11/13/24
-0.01 (-0.31%)
since 09/27/24
52-Week
2.67 +22.08%
on 12/20/24
7.56 -56.88%
on 05/21/24
-0.80 (-19.63%)
since 12/27/23

Most Recent Stories

More News
Daré Bioscience Initiates Phase 3 Study for Sildenafil Cream as Potential First FDA-Approved Treatment for Female Sexual Arousal Disorder

Daré Bioscience announces plans for a Phase 3 study of Sildenafil Cream for treating female sexual arousal disorder (FSAD).Quiver AI SummaryDaré Bioscience, in collaboration with Strategic Science &...

DARE : 3.26 (-1.21%)
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

DARE : 3.26 (-1.21%)
Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

DARE : 3.26 (-1.21%)
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

DARE : 3.26 (-1.21%)
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

DARE : 3.26 (-1.21%)
Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

DARE : 3.26 (-1.21%)
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

DARE : 3.26 (-1.21%)
Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

DARE : 3.26 (-1.21%)
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

DARE : 3.26 (-1.21%)
Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

June 30, 2022: $32.1 million in cash and cash equivalentsJuly 2022: approximately $18.0 million in cash received subsequent to quarter-end: $10.0 million...

DARE : 3.26 (-1.21%)

Business Summary

Dare Bioscience, Inc. is a healthcare company. It involved in the development and commercialization of products in women's reproductive health. Dare Bioscience, Inc., formerly known as Cerulean Pharma Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 3.53
2nd Resistance Point 3.44
1st Resistance Point 3.37
Last Price 3.26
1st Support Level 3.20
2nd Support Level 3.11
3rd Support Level 3.04

See More

52-Week High 7.56
Fibonacci 61.8% 5.69
Fibonacci 50% 5.12
Fibonacci 38.2% 4.54
Last Price 3.26
52-Week Low 2.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar